Insider Selling: Arcus Biosciences (NYSE:RCUS) COO Sells 11,225 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) COO Jennifer Jarrett sold 11,225 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $245,603.00. Following the transaction, the chief operating officer owned 203,007 shares of the company’s stock, valued at $4,441,793.16. This trade represents a 5.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jennifer Jarrett also recently made the following trade(s):

• On Wednesday, December 17th, Jennifer Jarrett sold 9,983 shares of Arcus Biosciences stock. The shares were sold at an average price of $22.16, for a total value of $221,223.28.
• On Monday, October 6th, Jennifer Jarrett sold 12,500 shares of Arcus Biosciences stock. The shares were sold at an average price of $14.54, for a total transaction of $181,750.00.
• On Wednesday, October 8th, Jennifer Jarrett sold 37,792 shares of Arcus Biosciences stock. The stock was sold at an average price of $15.05, for a total transaction of $568,769.60.

Arcus Biosciences Trading Down 1.2%

Shares of NYSE:RCUS traded down $0.26 during trading on Thursday, reaching $22.02. The stock had a trading volume of 1,175,874 shares, compared to its average volume of 1,200,446. Arcus Biosciences, Inc. has a 52 week low of $6.50 and a 52 week high of $26.40. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The firm’s fifty day moving average is $20.82 and its 200 day moving average is $13.98. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -6.40 and a beta of 0.75.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business had revenue of $26.00 million for the quarter, compared to analysts’ expectations of $19.89 million. During the same quarter in the prior year, the firm posted ($1.00) earnings per share. The business’s quarterly revenue was down 45.8% compared to the same quarter last year. As a group, equities analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcus Biosciences

A number of large investors have recently modified their holdings of the company. GAMMA Investing LLC grew its position in Arcus Biosciences by 59.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after purchasing an additional 1,021 shares during the period. SBI Securities Co. Ltd. grew its holdings in shares of Arcus Biosciences by 13,547.6% during the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after buying an additional 2,845 shares during the last quarter. CWM LLC grew its holdings in shares of Arcus Biosciences by 233.6% during the second quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after buying an additional 3,810 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Arcus Biosciences by 34.3% during the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock worth $57,000 after acquiring an additional 1,796 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Arcus Biosciences by 440.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock worth $62,000 after acquiring an additional 6,191 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on RCUS shares. Truist Financial set a $30.00 target price on Arcus Biosciences in a research note on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. UBS Group reiterated a “buy” rating on shares of Arcus Biosciences in a research note on Monday. HC Wainwright increased their target price on shares of Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Finally, Wedbush set a $35.00 price target on shares of Arcus Biosciences and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.89.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.